These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19515843)

  • 1. Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex.
    Drury JE; Di Costanzo L; Penning TM; Christianson DW
    J Biol Chem; 2009 Jul; 284(30):19786-90. PubMed ID: 19515843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of human liver Delta4-3-ketosteroid 5beta-reductase (AKR1D1) and implications for substrate binding and catalysis.
    Di Costanzo L; Drury JE; Penning TM; Christianson DW
    J Biol Chem; 2008 Jun; 283(24):16830-9. PubMed ID: 18407998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and catalytic mechanism of human steroid 5beta-reductase (AKR1D1).
    Di Costanzo L; Drury JE; Christianson DW; Penning TM
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):191-8. PubMed ID: 18848863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid recognition and regulation of hormone action: crystal structure of testosterone and NADP+ bound to 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase.
    Bennett MJ; Albert RH; Jez JM; Ma H; Penning TM; Lewis M
    Structure; 1997 Jun; 5(6):799-812. PubMed ID: 9261071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of human steroid 5β-reductase (AKR1D1) into 3β-hydroxysteroid dehydrogenase by single point mutation E120H: example of perfect enzyme engineering.
    Chen M; Drury JE; Christianson DW; Penning TM
    J Biol Chem; 2012 May; 287(20):16609-22. PubMed ID: 22437839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of steroid double-bond reduction catalysed by the human steroid 5β-reductase (AKR1D1) is sensitive to steroid structure: implications for steroid metabolism and bile acid synthesis.
    Jin Y; Chen M; Penning TM
    Biochem J; 2014 Aug; 462(1):163-71. PubMed ID: 24894951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-Depth Dissection of the P133R Mutation in Steroid 5β-Reductase (AKR1D1): A Molecular Basis of Bile Acid Deficiency.
    Chen M; Jin Y; Penning TM
    Biochemistry; 2015 Oct; 54(41):6343-51. PubMed ID: 26418565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia.
    Weisser H; Krieg M
    J Steroid Biochem Mol Biol; 1998 Oct; 67(1):49-55. PubMed ID: 9780029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1).
    Chen M; Drury JE; Penning TM
    Steroids; 2011 Apr; 76(5):484-90. PubMed ID: 21255593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride.
    Xiao Q; Wang L; Supekar S; Shen T; Liu H; Ye F; Huang J; Fan H; Wei Z; Zhang C
    Nat Commun; 2020 Oct; 11(1):5430. PubMed ID: 33110062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
    Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
    Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of human Delta4-3-ketosteroid 5beta-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition.
    Faucher F; Cantin L; Luu-The V; Labrie F; Breton R
    Biochemistry; 2008 Dec; 47(51):13537-46. PubMed ID: 19075558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
    Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
    Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crystal structure of human Delta4-3-ketosteroid 5beta-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism.
    Faucher F; Cantin L; Luu-The V; Labrie F; Breton R
    Biochemistry; 2008 Aug; 47(32):8261-70. PubMed ID: 18624455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning, expression and characterization of rhesus macaque types 1 and 2 5alpha-reductase: evidence for mechanism-based inhibition by finasteride.
    Ellsworth KP; Azzolina BA; Cimis G; Bull HG; Harris GS
    J Steroid Biochem Mol Biol; 1998 Sep; 66(5-6):271-9. PubMed ID: 9749833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5β-Reduced steroids and human Δ(4)-3-ketosteroid 5β-reductase (AKR1D1).
    Chen M; Penning TM
    Steroids; 2014 May; 83():17-26. PubMed ID: 24513054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
    Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
    Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.